FRO Peptides sells research compounds strictly for laboratory and research use only. Products are not for human consumption. You must be 21 years of age or older to enter this site.
Tirzepatide activates two receptors, GIP and GLP-1, built into a single 39-amino acid peptide. That dual mechanism is why researchers treat it as a distinct case rather than a simple upgrade on single-agonist compounds like semaglutide. Two Receptors, One Molecule GIP and GLP-1 both stimulate insulin release, but through separate receptors and separate downstream signaling. […]
Retatrutide is the first triple hormone receptor agonist to reach late-stage trials, activating GLP-1, GIP, and glucagon receptors in a single molecule. Semaglutide works on GLP-1 alone. Tirzepatide adds GIP. Retatrutide adds glucagon receptor activity on top of both, and that third mechanism is what separates its research profile from the other two. Why the […]
Semaglutide is a GLP-1 receptor agonist built on the structure of human glucagon-like peptide-1, with two changes that extend its activity: an amino acid substitution that blocks the enzyme DPP-4 from breaking it down, and a fatty acid chain that lets it bind albumin in the bloodstream. Native GLP-1 lasts minutes. Semaglutide lasts close to […]
